Novartis' experimental Cushing's disease drug meets goal in late-stage study

Novartis' experimental Cushing's disease drug meets goal in late-stage study by Lianne Dane
Novartis on Wednesday announced that in a late-stage study, SOM230 helped reduce urinary free cortisol levels in patients with Cushing's disease. Based on results of the study, the drugmaker said it would pursue regulatory approval of the drug by the end of the year.

Reference Articles
Novartis’s SOM230 shows promise in Cushing’s disease - (Bloomberg)
Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing's disease, a debilitating hormonal disorder - (Novartis)
Novartis Cushing's drug passes late-stage test - (TheStreet.com)

**Published in "First Word"